High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 7, 2014, Pages 979-985

  Al Kadhimi, Zaid ^a   Gul, Zartash ^b   Chen, Wei ^c   Smith, Daryn ^c   Abidi, Muneer ^c   Deol, Abhinav ^c   Ayash, Lois ^c   Lum, Lawrence ^c   Waller, Edmund K ^a   Ratanatharathorn, Voravit ^c   Uberti, Joseph ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Mycophenolate mofetil; Tacrolimus

Indexed keywords

HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HLA MATCHING; HLA SYSTEM; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONRELAPSE MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; SIBLING; TREATMENT DURATION; UNRELATED DONORS; VIRUS REACTIVATION; WHOLE BODY RADIATION; ACUTE DISEASE; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; DONOR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84902072440     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.016     Document Type: Article

References (52)

1. Chang Y.J., Weng C.L., Sun L.X., Zhao Y.T. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2012, 91:427-437.
2. Valcarcel D., Sierra J., Wang T., et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant 2011, 17:640-648.
3. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002, 99:1971-1977.
4. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
5. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
6. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
7. Eugui E.M., Allison A.C. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993, 685:309-329.
8. Storb R., Yu C., Zaucha J.M., et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999, 94:2523-2529.
9. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
10. Feinstein L., Sandmaier B., Maloney D., et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci 2001, 938:328-337. discussion 337-329.
11. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620-1629.
12. Rodriguez R., Parker P., Nademanee A., et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004, 33:1123-1129.
13. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
14. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005, 11:495-505.
15. Mohty M., de Lavallade H., Faucher C., et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:527-530.
16. Le Blanc K., Remberger M., Uzunel M., et al. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004, 78:1014-1020.
17. Nieto Y., Patton N., Hawkins T., et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006, 12:217-225.
18. Sabry W., Le Blanc R., Labbe A.C., et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009, 15:919-929.
19. Zohren F., Schroeder T., Czibere A., et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. Bone Marrow Transplant 2011, 46:747-755.
20. Perkins J., Field T., Kim J., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Al-Kadhimi Z., Gul Z., Rodriguez R., et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1734-1744.
24. Ratanatharathorn V., Karanes C., Lum L.G., et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992, 9:49-55.
25. Law L.Y., Horning S.J., Wong R.M., et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2006, 12:703-711.
26. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
27. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010, 45:1347-1351.
28. Cutler C, Logan BR, Nakamura R, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. ASH Annual Meeting Abstracts Blood 2012;120:739.
29. Wakahashi K., Yamamori M., Minagawa K., et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol 2011, 94:193-202.
30. McDermott C.L., Sandmaier B.M., Storer B., et al. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:1159-1166.
31. Nishikawa S., Okamura A., Yamamori M., et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplant Proc 2009, 41:3873-3876.
32. Yanada M., Naoe T., Iida H., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005, 36:867-872.
33. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
34. Ringden O., Labopin M., Gorin N.C., et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004, 22:416-423.
35. Remberger M., Naseh N., Aschan J., et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003, 32:217-223.
36. Bishop M.R., Tarantolo S.R., Geller R.B., et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000, 96:80-85.
37. Ozcan M., Ustun C., Akcaglayan E., et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 27:499-505.
38. Khoury H.J., Loberiza F.R., Ringden O., et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006, 107:1712-1716.
39. Przepiorka D., Smith T.L., Folloder J., et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001, 97:3405-3410.
40. Stinson T.J., Adams J.R., Bishop M.R., et al. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000, 26:663-666.
41. Ho V.T., Mirza N.Q., Junco Dd D., et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003, 32:771-775.
42. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
43. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
44. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
45. Martires K.J., Baird K., Steinberg S.M., et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011, 118:4250-4257.
46. Passweg J.R., Zhang M.J., Rocha V., et al. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:1869-1873.
47. Saliba R.M., de Lima M., Giralt S., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007, 109:2751-2758.
48. Wojnar J., Giebel S., Krawczyk-Kulis M., et al. Acute graft-versus-host disease. The incidence and risk factors. Ann Transplant 2006, 11:16-23.
49. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
50. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:885-892.
51. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012, 30:3202-3208.
52. Choi S.W., Braun T., Chang L., et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014, 15:87-95.